Home   Business   Article

Subscribe Now

Biofidelity confirms scientific advisory board as it heads towards launch of ASPYRE-Lung diagnostic test

Biofidelity has confirmed the initial members of its new scientific advisory board, who will help guide its molecular diagnostic products.

Biofidelity has moved into its new Cambridge Science Park
Biofidelity has moved into its new Cambridge Science Park

The Cambridge Science Park company has appointed:

  • Dr Mace Rothenberg, former CMO, Pfizer
  • Dr Hesham Abdullah, head of oncology global clinical development, GSK
  • Dr Jerald Radich, professor and Kurt Enslein endowed chair, Fred Hutchinson Cancer Research Center
  • Andrea Conners, executive director, Patient Empowerment Network
  • Phylicia L Woods, executive director, Cancer Policy Institute, Cancer Support Community

Biofidelity’s ASPYRE technology enables simple, decentralised multi-gene testing in a fraction of the time and at a fraction of the cost of current technologies.

It has the ability to perform the ultra-sensitive detection of panels of DNA and RNA mutations from tissue or blood using existing real-time PCR platforms, offering actionable results in hours.

It expects to launch its first commercial diagnostic assay, ASPYRE-Lung - formerly Identi-Lung - later this year through its recently established US headquarters and cancer diagnostic laboratory in Research Triangle Park, NC.

Barnaby Balmforth, CEO of Biofidelity
Barnaby Balmforth, CEO of Biofidelity

CEO Dr Barnaby Balmforth said: “Biofidelity’s disruptive technology is designed to revolutionise access to best-in-class cancer diagnostics, breaking down barriers to better screening, monitoring and treatment for all cancer patients.

“Dr Mace Rothenberg, Dr Hesham Abdullah and Dr Jerald Radich have an extraordinary track record of service to cancer patients at the world’s leading pharmaceutical companies and research centres, while Andrea Conners and Phylicia Woods have been tremendous advocates for patients and for access to precision medicine.

“We are greatly honoured and encouraged by their commitment to support the potential of ASPYRE to provide oncologists with rapid, clinically actionable data to enable the right cancer treatment to be prescribed at the right time.”

Read more

Biofidelity lines up first product after being granted key patent in US protect its cancer diagnosis technology

Biofidelity moves to larger Cambridge Science Park HQ and appoints Dr Robert Osborne as COO

Biofidelity’s $12m will help it transform cancer diagnostics

Winners of Cambridge Independent Science and Technology Awards revealed

Sign up for our weekly newsletter and get the latest on Cambridge life sciences direct to your inbox every Friday

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies - Learn More